Merck (MRK) Long-Term Investments (2009 - 2026)

Merck has disclosed Long-Term Investments across 18 years of filings, most recently posting $1.1 billion for Q1 2026.

• In Q1 2026, Long-Term Investments rose 343.78% year-over-year to $1.1 billion; the TTM figure through Mar 2026 stood at $1.1 billion (up 343.78% YoY), while the FY2025 annual figure was $956.0 million, up 106.48% from the prior year.
• Long-Term Investments improved to $1.1 billion in Q1 2026, from $956.0 million in the prior quarter.
• Over the last five years, Long-Term Investments for MRK reached as high as $1.3 billion in Q3 2023 and fell as low as $238.0 million in Q2 2022.
• The 5-year median for Long-Term Investments is $622.0 million (2023), against an average of $635.0 million.
• Annual changes were most pronounced in 2023 — Long-Term Investments slumped 75.17% — and 2026, when it jumped 343.78%.
• A 5-year view of Long-Term Investments shows it stood at $1.0 billion in 2022, then tumbled by 75.17% to $252.0 million in 2023, then jumped by 83.73% to $463.0 million in 2024, then soared by 106.48% to $956.0 million in 2025, then advanced by 15.59% to $1.1 billion in 2026.
• According to Business Quant data, Long-Term Investments over the past three periods registered $1.1 billion, $956.0 million, and $1.1 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.